Appendix GCorrelation Table for KQ 2

Table G-1. Correlation table for KQ 2 (management of PAH).

Table G-1

Correlation table for KQ 2 (management of PAH).

References Cited in Appendix G

1.
Andreassen AK, Wergeland R, Simonsen S, et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol. 2006;98(4):525–9. [PubMed: 16893710]
2.
Bendayan D, Shitrit D, Ygla M, et al. Hyperuricemia as a prognostic factor in pulmonary arterial hypertension. Respir Med. 2003;97(2):130–3. [PubMed: 12587962]
3.
Bernus A, Wagner BD, Accurso F, et al. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest. 2009;135(3):745–51. [PMC free article: PMC2715554] [PubMed: 18849405]
4.
Borges AC, Knebel F, Eddicks S, et al. Right ventricular function assessed by two-dimensional strain and tissue Doppler echocardiography in patients with pulmonary arterial hypertension and effect of vasodilator therapy. Am J Cardiol. 2006;98(4):530–4. [PubMed: 16893711]
5.
Campana C, Pasotti M, Monti L, et al. The evaluation of right ventricular performance in different clinical models of heart failure. Eur Heart J Suppl. 2004;6(6):F61–F67.
6.
Cella G, Vianello F, Cozzi F, et al. Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. J Rheumatol. 2009;36(4):760–7. [PubMed: 19208592]
7.
Chin KM, Channick RN, Kim NH, et al. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels. Chest. 2007;132(3):786–92. [PubMed: 17646224]
8.
Dyer KL, Pauliks LB, Das B, et al. Use of myocardial performance index in pediatric patients with idiopathic pulmonary arterial hypertension. J Am Soc Echocardiogr. 2006;19(1):21–7. [PMC free article: PMC1934985] [PubMed: 16423665]
9.
Fahmy Elnoamany M, Abdelraouf Dawood A. Right ventricular myocardial isovolumic relaxation time as novel method for evaluation of pulmonary hypertension: correlation with endothelin-1 levels. J Am Soc Echocardiogr. 2007;20(5):462–9. [PubMed: 17484984]
10.
Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006;129(5):1313–21. [PubMed: 16685024]
11.
Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006;174(9):1034–41. [PubMed: 16888289]
12.
Friedberg MK, Feinstein JA, Rosenthal DN. A novel echocardiographic Doppler method for estimation of pulmonary arterial pressures. J Am Soc Echocardiogr. 2006;19(5):559–62. [PubMed: 16644441]
13.
Gan CT, McCann GP, Marcus JT, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. Eur Respir J. 2006;28(6):1190–4. [PubMed: 16971413]
14.
Ghofrani HA, Wiedemann R, Rose F, et al. Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders. Eur Respir J. 2002;19(4):664–71. [PubMed: 11998996]
15.
Goto K, Arai M, Watanabe A, et al. Utility of echocardiography versus BNP level for the prediction of pulmonary arterial pressure in patients with pulmonary arterial hypertension. Int Heart J. 2010;51(5):343–7. [PubMed: 20966607]
16.
Grubstein A, Benjaminov O, Dayan DB, et al. Computed tomography angiography in pulmonary hypertension. Isr Med Assoc J. 2008;10(2):117–20. [PubMed: 18432023]
17.
Haddad F, Zamanian R, Beraud AS, et al. A novel non-invasive method of estimating pulmonary vascular resistance in patients with pulmonary arterial hypertension. J Am Soc Echocardiogr. 2009;22(5):523–9. [PubMed: 19307098]
18.
Heresi GA, Aytekin M, Newman J, et al. CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival. Lung. 2010;188(3):191–7. [PMC free article: PMC2886668] [PubMed: 20186422]
19.
Heresi GA, Tang WH, Aytekin M, et al. Sensitive cardiac troponin I predicts poor outcomes in pulmonary arterial hypertension. Eur Respir J. 2012;39(4):939–44. [PubMed: 21885398]
20.
Hinderliter AL, Willis PWt, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group Circulation. 1997;95(6):1479–86. [PubMed: 9118516]
21.
Homma A, Anzueto A, Peters JI, et al. Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterization in patients awaiting lung transplantation. J Heart Lung Transplant. 2001;20(8):833–9. [PubMed: 11502405]
22.
Leuchte HH, Holzapfel M, Baumgartner RA, et al. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest. 2005;128(4):2368–74. [PubMed: 16236896]
23.
Machado RF, Anthi A, Steinberg MH, et al. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA. 2006;296(3):310–8. [PubMed: 16849664]
24.
Machado RF, Londhe Nerkar MV, Dweik RA, et al. Nitric oxide and pulmonary arterial pressures in pulmonary hypertension. Free Radic Biol Med. 2004;37(7):1010–7. [PubMed: 15336317]
25.
Montani D, Souza R, Binkert C, et al. Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension. Chest. 2007;131(1):101–8. [PubMed: 17218562]
26.
Morishita T, Miyaji K, Akao I, et al. The ratio of the atrial areas reflects the clinical status of patients with pulmonary arterial hypertension. J Med Ultrason. 2009;36(4):201–206.
27.
Mukerjee D, Yap LB, Holmes AM, et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med. 2003;97(11):1230–6. [PubMed: 14635979]
28.
Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102(8):865–70. [PubMed: 10952954]
29.
Nath J, Demarco T, Hourigan L, et al. Correlation between right ventricular indices and clinical improvement in epoprostenol treated pulmonary hypertension patients. Echocardiography. 2005;22(5):374–9. [PubMed: 15901287]
30.
Nickel N, Kempf T, Tapken H, et al. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178(5):534–41. [PubMed: 18565955]
31.
Pyxaras SA, Pinamonti B, Barbati G, et al. Echocardiographic evaluation of systolic and mean pulmonary artery pressure in the follow-up of patients with pulmonary hypertension. Eur J Echocardiogr. 2011;12(9):696–701. [PubMed: 21821609]
32.
Souza R, Jardim C, Julio Cesar, Fernandes C, et al. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respir Med. 2007;101(1):69–75. [PubMed: 16781131]
33.
Takatsuki S, Wagner BD, Ivy DD. B-type Natriuretic Peptide and Amino-terminal Pro-B-type Natriuretic Peptide in Pediatric Patients with Pulmonary Arterial Hypertension. Congenital Heart Disease. 2012;7(3):259–267. [PMC free article: PMC3355223] [PubMed: 22325151]
34.
Utsunomiya H, Nakatani S, Nishihira M, et al. Value of estimated right ventricular filling pressure in predicting cardiac events in chronic pulmonary arterial hypertension. J Am Soc Echocardiogr. 2009;22(12):1368–74. [PubMed: 19944957]
35.
Van Albada ME, Loot FG, Fokkema R, et al. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Res. 2008;63(3):321–7. [PubMed: 18287971]
36.
Vizza CD, Letizia C, Badagliacca R, et al. Relationship between baseline ET-1 plasma levels and outcome in patients with idiopathic pulmonary hypertension treated with bosentan. Int J Cardiol. 2012 [PubMed: 22265324]
37.
Voelkel MA, Wynne KM, Badesch DB, et al. Hyperuricemia in severe pulmonary hypertension. Chest. 2000;117(1):19–24. [PubMed: 10631193]
38.
Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 2006;27(12):1485–94. [PubMed: 16682379]
39.
Zafrir N, Zingerman B, Solodky A, et al. Use of noninvasive tools in primary pulmonary hypertension to assess the correlation of right ventricular function with functional capacity and to predict outcome. Int J Cardiovasc Imaging. 2007;23(2):209–15. [PubMed: 16972146]